Bioxytran registers Indian subsidiary, Pharmalectin India, to commercialize ProLectin-M pending CDSCO approval

BIOXYTRAN, INC

Wholly owned subsidiary Pharmalectin India Private Limited registered on Sept 7, 2022 in India.
Subsidiary to sponsor clinical trials and commercialize Bioxytran's products if CDSCO approval is obtained.
Indian manufacturing plant is FDA-approved; no distributor identified yet.
Press release and updated corporate presentation issued Dec 14, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.